<DOC>
	<DOCNO>NCT01428583</DOCNO>
	<brief_summary>The study provide information ass benefit versus risk extend exposure oxycodone HCl naltrexone HCl extended-release capsule chronic noncancer pain population .</brief_summary>
	<brief_title>Safety Study Oxycodone Hydrochloride Naltrexone Hydrochloride Extended-Release Capsules Subjects With Moderate Severe Chronic Noncancer Pain</brief_title>
	<detailed_description />
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Subject moderate severe chronic noncancer pain ( duration least 3 month ) require continuous aroundtheclock opioid analgesic extended period time . Conditions may include , limited , osteoarthritis , chronic low back pain , opioid responsive pain condition . Subject agree refrain take opioid medication study drug study . ( The exception PreTreatment Period subject may continue current opioid therapy guide first 4 week Treatment Period subject may administer immediaterelease oxycodone support conversion study drug . ) Subject moderate severe chronic pain due cancer , migraine , recent trauma , infection , pain expect shortterm ( duration le 3 month ) . Subject documented history alcohol drug abuse within 1 year prior study entry Investigator 's judgment would impact subject participation . Subject ongoing active alcohol drug abuse Investigator 's judgment would impact subject participation . Subject positive urine drug test illicit drug use medication screen without legitimate medical explanation . Subject clinically significant medical condition ( e.g. , cardiovascular , neurological , renal , hepatic , pulmonary , gastrointestinal , endocrine , hematological , immunological , rheumatological , metabolic , psychiatric ) physical examination , vital sign ( VS ) , 12lead electrocardiogram ( ECG ) , clinical laboratory abnormality opinion Investigator would impact safety subject study participation . If female , subject pregnant breastfeeding . Subject known history know hypersensitivity oxycodone , oxycodone salt , naltrexone acetaminophen , pharmacological similar compound . Subject historically nonresponsive oxycodone treatment require great 160 mg oxycodone 24hour time interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic noncancer pain</keyword>
	<keyword>oxycodone</keyword>
	<keyword>naltrexone</keyword>
</DOC>